-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Addressing Unmet Needs in T Cell Lymphomas

Program: Education Program
Hematology Disease Topics & Pathways:
Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Transplantation (Allogeneic and Autologous)
Monday, December 9, 2024: 4:30 PM-5:45 PM
Ballroom 20AB (San Diego Convention Center)

Description:
The rare nature of peripheral and cutaneous T-cell lymphomas, variable clinical course and only recently evolving understanding of their unique biology make the care of patients with these disease particularly difficult. This educational session will delve into current clinical challenges in management of this difficult to treat population and will focus on the more common subtypes of peripheral T-cell lymphoma and cutaneous T-cell lymphomas.  The session first will discuss management, incorporation of novel agents and consideration of personalized approaches in relapsed/refractory peripheral T-cell lymphomas and cutaneous T-cell lymphomas. We will also discuss the utility and timing of both autologous and allogeneic transplant in cutaneous and peripheral T-cell lymphoma.  

Dr. Mehta-Shah will discuss current clinical challenges in the management of patients with relapsed/refractory T-cell lymphomas.  In the evolving landscape of treatment and biologic considerations, we will discuss the use of both standard agents as well as novel targeted agents in the treatment of this patient population. Given that our understanding of these heterogenous diseases continues to improve, we will discuss strategies for subtypes specific or personalized therapy.

Dr. Horwitz will explore and detail the expanding options for treatment of CTCL.

Dr. Dreger will discuss the role of stem cell transplant (auto and allo) on PTCL and CTCL.

Chair:
Neha Mehta-Shah, MD, ARRAY(0xda33554)
Disclosures:
Mehta-Shah: Daiichi Sankyo: Consultancy, Research Funding; Celgene: Research Funding; Secura Bio: Consultancy, Research Funding; Genetech/Roche: Consultancy, Research Funding; Johnson & Johnson/Janssen: Consultancy; Pfizer: Consultancy; Morphosys: Research Funding; Innate Pharmaceuticals: Research Funding; Verastem Oncology: Research Funding; Yingli Pharmaceuticals: Research Funding; C4 Therapeutics: Consultancy, Research Funding; Dizal Pharmaceuticals: Research Funding; Bristol Myers-Squibb: Research Funding; Astra Zeneca: Consultancy, Research Funding; Corvus Pharmaceuticals: Research Funding; Kyowa Hakko Kirin, Karyopharm Therapeutics: Consultancy.

The rare nature of peripheral and cutaneous T-cell lymphomas, variable clinical course and only recently evolving understanding of their unique biology make the care of patients with these disease particularly difficult. This educational session will delve into current clinical challenges in management of this difficult to treat population and will focus on the more common subtypes of peripheral T-cell lymphoma and cutaneous T-cell lymphomas.  The session first will discuss management, incorporation of novel agents and consideration of personalized approaches in relapsed/refractory peripheral T-cell lymphomas and cutaneous T-cell lymphomas. We will also discuss the utility and timing of both autologous and allogeneic transplant in cutaneous and peripheral T-cell lymphoma.  

Dr. Mehta-Shah will discuss current clinical challenges in the management of patients with relapsed/refractory T-cell lymphomas.  In the evolving landscape of treatment and biologic considerations, we will discuss the use of both standard agents as well as novel targeted agents in the treatment of this patient population. Given that our understanding of these heterogenous diseases continues to improve, we will discuss strategies for subtypes specific or personalized therapy.

Dr. Horwitz will explore and detail the expanding options for treatment of CTCL.

Dr. Dreger will discuss the role of stem cell transplant (auto and allo) on PTCL and CTCL.

Neha Mehta-Shah, MD

Siteman Cancer Center, Washington University in St. Louis, St Louis, MO

Steven Horwitz, MD

Memorial Sloan-Kettering Cancer Center, New York, NY

Peter Dreger, MD

Universitätsklinikum, Heidelberg, Germany

See more of: Education Program